NNMT inhibitor (small molecule) · Also known as 5-amino-1-methylquinolinium
A small molecule that inhibits nicotinamide N-methyltransferase (NNMT), an enzyme involved in cellular energy metabolism. By blocking NNMT, it increases intracellular NAD+ levels and promotes fat metabolism.
5-Amino-1MQ emerged from research into NNMT's role in obesity and metabolic dysfunction. A 2018 study in Biochemical Pharmacology showed that NNMT inhibitors reversed high-fat-diet-induced obesity in mice without affecting food intake. It is not technically a peptide but is frequently grouped with peptide therapies in clinical practice.
NNMT is an enzyme that degrades nicotinamide (a precursor to NAD+) by methylating it into 1-methylnicotinamide (1-MNA). When NNMT activity is high, especially in fat tissue, it drains the pool of nicotinamide available for NAD+ synthesis. Lower NAD+ levels impair cellular energy metabolism and promote fat storage.
5-Amino-1MQ selectively inhibits NNMT without affecting related methyltransferases or other NAD+ salvage pathway enzymes. In animal studies, this led to increased intracellular NAD+ levels, suppressed lipogenesis (fat creation) in adipocytes, and reduced white adipose tissue mass. Treated mice lost significant body weight and fat without eating less food, suggesting the effect is driven by metabolic changes rather than appetite suppression.
50 mg/day oral
Weeks 1-250-150 mg/day oral
4-12 week cyclesMost side effects tend to improve as your body adjusts.